Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. 2018 Jan 11;378(2):169-80. [Pubmed]
Inojosa H, Proschmann U, Akgün K, Ziemssen T. The need for a strategic therapeutic approach: multiple sclerosis in check. Ther Adv Chronic Dis. 2022 Jan 18;13:20406223211063032. [Pubmed]
Iaffaldano P, Lucisano G, Butzkueven H, Hillert J, Hyde R, Koch-Henriksen N, et al. Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. Mult Scler. 2021 Sep;27(10):1543-55. [Pubmed]
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-73. [Pubmed]
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227-31. [Pubmed]
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 Jul;50(1):121-7. [Pubmed]
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 Feb;69(2):292-302. [Pubmed]
Tintore M, Cobo-Calvo A, Carbonell P, Arrambide G, Otero-Romero S, Río J, et al. Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. Neurology. 2021 Oct 26;97(17):e1641-e1652. [Pubmed]
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al.; ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017 Jan 19;376(3):209-20. [Pubmed]
Simonsen CS, Flemmen HØ, Lauritzen T, Berg-Hansen P, Moen SM, Celius EG. The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis. Mult Scler J Exp Transl Clin. 2020 Jan 22;6(1):2055217319901291. [Pubmed]
Reiber H, Ungefehr S, Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler. 1998 Jun;4(3):111-7. [Pubmed]
Sádaba MC, González Porqué P, Masjuán J, Álvarez-Cermeño JC, Bootello A, Villar LM. An ultrasensitive method for the detection of oligoclonal IgG bands. J Immunol Methods. 2004 Jan;284(1-2):141-5. [Pubmed]
Abraira V, Álvarez-Cermeño JC, Arroyo R, Cámara C, Casanova B, Cubillo S, et al. Utility of oligoclonal IgG band detection for MS diagnosis in daily clinical practice. J Immunol Methods. 2011 Aug 31;371(1-2):170-3. [Pubmed]
Villar LM, Masjuán J, Sádaba MC, González-Porqué P, Plaza J, Bootello A, Álvarez-Cermeño JC. Early differential diagnosis of multiple sclerosis using a new oligoclonal band test. Arch Neurol. 2005 Apr;62(4):574-7. [Pubmed]
Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):909-14. [Pubmed]
Tintore M, Rovira À, Río J, Otero-Romero S, Arrambide G, Tur C, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015 Jul;138(Pt 7):1863-74. [Pubmed]
Matute-Blanch C, Villar LM, Álvarez-Cermeño JC, Rejdak K, Evdoshenko E, Makshakov G, et al. Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain. 2018 Apr 1;141(4):1085-93. [Pubmed]
Villar LM, Espiño M, Costa-Frossard L, Muriel A, Jiménez J, Álvarez-Cermeño JC. High levels of cerebrospinal fluid free kappa chains predict conversion to multiple sclerosis. Clin Chim Acta. 2012 Nov 20;413(23-24):1813-6. [Pubmed]
Senel M, Tumani H, Lauda F, Presslauer S, Mojib-Yezdani R, Otto M, Brettschneider J. Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis. PLoS One. 2014 Apr 2;9(4):e88680. [Pubmed]
Leurs CE, Twaalfhoven H, Lissenberg-Witte BI, van Pesch V, Dujmovic I, Drulovic J, et al. Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. Mult Scler. 2020 Jul;26(8):912-23. [Pubmed]
Arrambide G, Espejo C, Eixarch H, Villar LM, Álvarez-Cermeño JC, Picón C, et al. Neurofilament light chain level is a weak risk factor for the development of MS. Neurology. 2016 Sep 13;87(11):1076-84. Erratum in: Neurology. 2016 Nov 8;87(19):2068. [Pubmed]
Monreal E, Sainz de la Maza S, Costa-Frossard L, Walo-Delgado P, Zamora J, Fernández-Velasco JI, et al. Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome. Neurol Neuroimmunol Neuroinflamm. 2021 Jul 22;8(5):e1047. [Pubmed]
Cantó E, Tintoré M, Villar LM, Costa C, Nurtdinov R, Álvarez-Cermeño JC, et al. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain. 2015 Apr;138(Pt 4):918-31. [Pubmed]